Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab

References

• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Antonia S, Villegas A, Danie D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Wit RD, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. doi:10.1056/NEJMoa2002788
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Bellmunt J, Fradet Y, et al. Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol. 2018;36(16):1579–1587. doi:10.1200/JCO.2017.76.9562
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–894. doi:10.1158/1078-0432.CCR-15-1136
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374–378. doi:10.1001/jamaoncol.2017.2925
   PubMed Web of Science ®Google Scholar
• Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–74. doi:10.1016/j.lungcan.2017.11.019
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Suzuki K, Hiraide M, et al. Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma. Oncology. 2020;98(4):237–242. doi:10.1159/000505340
   PubMed Web of Science ®Google Scholar
• Kijima T, Fukushima H, Kusuhara S, et al. Association between the occurrence and spectrum of immune-related adverse events and efficacy of pembrolizumab in asian patients with advanced urothelial cancer: multicenter retrospective analyses and systematic literature review. Clin Genitourin Cancer. 2021;19(3):208–216.e1. doi:10.1016/j.clgc.2020.07.003
   PubMed Web of Science ®Google Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–965. doi:10.2147/OTT.S153290
   PubMed Web of Science ®Google Scholar
• Kawai T, Sato Y, Makino K, et al. Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. Eur J Cancer. 2019;116:114–115. doi:10.1016/j.ejca.2019.05.017
   PubMed Web of Science ®Google Scholar
• Yasuoka S, Yuasa T, Nishimura N, et al. Initial experience of pembrolizumab therapy in Japanese patients with metastatic urothelial cancer. Anticancer Res. 2019;39(7):3887–3892. doi:10.21873/anticanres.13539
   PubMed Web of Science ®Google Scholar
• Ogihara K, Kikuchi E, Shigeta K, et al. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol Oncol. 2020;38(6):602.e1–602.e10. doi:10.1016/j.urolonc.2020.02.005
   PubMed Web of Science ®Google Scholar
• Furubayashi N, Minato A, Negishi T, et al. The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab. Cancer Manag Res. 2021;13:8049–8056. doi:10.2147/CMAR.S333823
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Ohashi H, Takeuchi S, Miyagaki T, et al. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma. Drug Discov Ther. 2020;14(3):117–121. doi:10.5582/ddt.2020.03043
   PubMed Web of Science ®Google Scholar
• Mota JM, Teo MY, Whiting K, et al. Pretreatment eosinophil counts in patients with advanced or metastatic urothelial carcinoma treated with anti-PD-1/PD-L1 checkpoint inhibitors. J Immunother. 2021;44(7):248–253. doi:10.1097/CJI.0000000000000372
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. NIoH, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0; 2017 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed October 1, 2021.
   Google Scholar
• Cortellini A, Chiari R, Ricciuti B, et al. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer. 2019;20(4):237–247.e1. doi:10.1016/j.cllc.2019.02.006
   PubMed Web of Science ®Google Scholar
• Bisschop C, Wind TT, Blank CU, et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch expanded access program. J Immunother. 2019;42(6):208–214. doi:10.1097/CJI.0000000000000271
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198. doi:10.1200/JCO.2015.60.8448
   PubMed Web of Science ®Google Scholar
• Toi Y, Sugawara S, Kawashima Y, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell Lung cancer treated with nivolumab. Oncologist. 2018;23(11):1358–1365. doi:10.1634/theoncologist.2017-0384
   PubMed Web of Science ®Google Scholar
• Ishihara H, Takagi T, Kondo T, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol. 2019;37(6):355.e21–355.e29. doi:10.1016/j.urolonc.2019.03.003
   PubMed Web of Science ®Google Scholar
• Ikeda T, Ishihara H, Nemoto Y, et al. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Urol Oncol. 2021;39(10):735.e9–735.e16. doi:10.1016/j.urolonc.2021.05.012
   Web of Science ®Google Scholar
• Eggermont AM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2020;6(4):519–527. doi:10.1001/jamaoncol.2019.5570
   PubMed Web of Science ®Google Scholar
• Simon SC, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer Immunol Immunother. 2019;68(5):823–833. doi:10.1007/s00262-018-2255-4
   PubMed Web of Science ®Google Scholar
• Simon HU, Plötz S, Simon D, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur J Immunol. 2003;33(4):834–839. doi:10.1002/eji.200323727
   PubMed Web of Science ®Google Scholar
• Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res. 1995;1(8):805–812.
   PubMed Web of Science ®Google Scholar
• Ellem KA, O’Rourke MG, Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother. 1997;44(1):10–20. doi:10.1007/s002620050349
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin Cancer Res. 2015;21(24):5453–5459. doi:10.1158/1078-0432.CCR-15-0676
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496. doi:10.1158/1078-0432.CCR-16-0127
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:10.1016/j.jtho.2017.10.030
   PubMed Web of Science ®Google Scholar
• Zahoor H, Barata PC, Jia X, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107. doi:10.1186/s40425-018-0425-8
   PubMed Web of Science ®Google Scholar
• Hude I, Sasse S, Bröckelmann PJ, et al. Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition. Br J Haematol. 2018;181(6):837–840. doi:10.1111/bjh.14705
   PubMed Web of Science ®Google Scholar
• Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 2020;150:76–82. doi:10.1016/j.lungcan.2020.08.015
   PubMed Web of Science ®Google Scholar
• Bottlaender L, Amini‑Adle M, Maucort‑Boulch D, et al. Cutaneous adverse events: a predictor of tumour response under anti‑PD‑1 therapy for metastatic melanoma, a cohort analysis of 189 patients. J Eur Acad Dermatol Venereol. 2020;34(9):2096–2105. doi:10.1111/jdv.16311
   PubMed Web of Science ®Google Scholar
• Krishnan T, Tomita Y, Roberts-Thomson R, et al. A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy. Future Sci OA. 2020;6(10):FSO608. doi:10.2144/fsoa-2020-0070
   PubMed Web of Science ®Google Scholar